PMID- 31083461
OWN - NLM
STAT- MEDLINE
DCOM- 20200106
LR  - 20200309
IS  - 2073-4409 (Print)
IS  - 2073-4409 (Electronic)
IS  - 2073-4409 (Linking)
VI  - 8
IP  - 5
DP  - 2019 May 10
TI  - Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK 
      Signaling.
LID - 10.3390/cells8050442 [doi]
LID - 442
AB  - Lung cancer is the most deadly neoplasm with the highest incidence in both 
      genders, with non-small cell lung cancer (NSCLC) being the most frequent subtype. 
      Somatic mutations within the tyrosine kinase domain of the epidermal growth 
      factor receptor (EGFR) gene are key drivers of NSCLC progression, with EGFR 
      inhibitors being particularly beneficial for patients carrying the so-called 
      "EGFR-sensitizing mutations". However, patients eventually acquire resistance to 
      these EGFR inhibitors, and a better knowledge of other driven and targetable 
      proteins will allow the design of increasingly accurate drugs against patients' 
      specific molecular aberrations. Raf kinase inhibitory protein (RKIP) is an 
      important modulator of relevant intracellular signaling pathways, including those 
      controlled by EGFR, such as MAPK. It has been reported that it has metastasis 
      suppressor activity and a prognostic role in several solid tumors, including lung 
      cancer. In the present review, the potential use of RKIP in the clinic as a 
      prognostic biomarker and predictor of therapy response in lung cancer is 
      addressed.
FAU - Raquel-Cunha, Ana
AU  - Raquel-Cunha A
AD  - Life and Health Sciences Research Institute (ICVS), School of Medicine, 
      University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal. 
      a.raquelfcunha@gmail.com.
AD  - ICVS/3Bs-PT Government Associate Laboratory, 4710-057 Braga/4805-017 Guimaraes, 
      Portugal. a.raquelfcunha@gmail.com.
FAU - Cardoso-Carneiro, Diana
AU  - Cardoso-Carneiro D
AD  - Life and Health Sciences Research Institute (ICVS), School of Medicine, 
      University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal. 
      diana.ccarneiro@gmail.com.
AD  - ICVS/3Bs-PT Government Associate Laboratory, 4710-057 Braga/4805-017 Guimaraes, 
      Portugal. diana.ccarneiro@gmail.com.
FAU - Reis, Rui M
AU  - Reis RM
AD  - Life and Health Sciences Research Institute (ICVS), School of Medicine, 
      University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal. 
      rreis@med.uminho.pt.
AD  - ICVS/3Bs-PT Government Associate Laboratory, 4710-057 Braga/4805-017 Guimaraes, 
      Portugal. rreis@med.uminho.pt.
AD  - Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Sao Paulo 
      14784 400, Brazil. rreis@med.uminho.pt.
FAU - Martinho, Olga
AU  - Martinho O
AD  - Life and Health Sciences Research Institute (ICVS), School of Medicine, 
      University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal. 
      olgamartinho@med.uminho.pt.
AD  - ICVS/3Bs-PT Government Associate Laboratory, 4710-057 Braga/4805-017 Guimaraes, 
      Portugal. olgamartinho@med.uminho.pt.
AD  - Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Sao Paulo 
      14784 400, Brazil. olgamartinho@med.uminho.pt.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20190510
PL  - Switzerland
TA  - Cells
JT  - Cells
JID - 101600052
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (PEBP1 protein, human)
RN  - 0 (Phosphatidylethanolamine Binding Protein)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Biomarkers, Tumor/*metabolism
MH  - Carcinoma, Non-Small-Cell Lung/*metabolism
MH  - Cell Line, Tumor
MH  - Drug Resistance, Neoplasm
MH  - ErbB Receptors/antagonists & inhibitors/genetics
MH  - Humans
MH  - Mutation/drug effects
MH  - Phosphatidylethanolamine Binding Protein/*physiology
MH  - Prognosis
MH  - Signal Transduction
PMC - PMC6562953
OTO - NOTNLM
OT  - EGFR
OT  - RKIP signaling
OT  - cancer therapy
OT  - lung cancer
OT  - prognosis
COIS- The authors declare no conflicts of interest.
EDAT- 2019/05/15 06:00
MHDA- 2019/05/15 06:01
PMCR- 2019/05/01
CRDT- 2019/05/15 06:00
PHST- 2019/03/01 00:00 [received]
PHST- 2019/05/04 00:00 [revised]
PHST- 2019/05/07 00:00 [accepted]
PHST- 2019/05/15 06:00 [entrez]
PHST- 2019/05/15 06:00 [pubmed]
PHST- 2019/05/15 06:01 [medline]
PHST- 2019/05/01 00:00 [pmc-release]
AID - cells8050442 [pii]
AID - cells-08-00442 [pii]
AID - 10.3390/cells8050442 [doi]
PST - epublish
SO  - Cells. 2019 May 10;8(5):442. doi: 10.3390/cells8050442.